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Aldosterone production occurs in the adrenal cortex,  and is regulated primarily by angiotensin II 
(Ang II),  potassium and adrenocorticotropin (ACTH).  In the presence of the aldosterone stimulators,  
steroidogenesis is further governed by local autocrine and/or paracrine factors in the adrenal cortex.  
We reported the presence of functional bone morphogenetic protein (BMP) system in the adrenal cor-
tex and also demonstrated that BMP-6 increases Ang II-induced aldosterone production,  which could 
be involved in the “aldosterone breakthrough” phenomenon.  Aldosterone breakthrough is the phenom-
enon by which circulating aldosterone concentrations increase above pre-treatment levels after long-
term therapy with ACE inhibitors or Ang II type 1 receptor antagonists (ARB).  This phenomenon may 
lead to important clinical consequences since increased aldosterone in a high-salt state facilitates car-
diovascular and renal damage in hypertensive patients.  We found that long-term ARB treatment 
reverses the reduction of aldosterone synthesis by adrenocortical cells,  thereby causing “cellular 
aldosterone breakthrough”.  The availability of BMP-6 in the adrenal cortex may be at least partly 
involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment 
with ARB.
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ngiotensin-converting enzyme (ACE) inhibitors 
and angiotensin II (Ang II) type 1 receptor 
(AT1R) blockers (ARB) play major roles in the medi-
cation for hypertension.  However,  plasma aldosterone 
levels occasionally increase after an initial decline in 
some patients over the course of long-term therapy 
with ACE inhibitors and/or ARB.  Aldosterone 
breakthrough is the phenomenon by which circulating 
aldosterone concentrations increase above pre-treat-
ment levels after long-term therapy with ACE inhibi-
tors [1,  2] and/or ARB [3,  4].  Staessen et al.  [1] 
ﬁrst reported the aldosterone breakthrough phenom-
enon in 1981.  As described in their report,  the 
plasma concentration of aldosterone was followed in 7 
hypertensive patients before and during long-term Ang 
II suppression with an orally active ACE inhibitor,  
captopril.  The plasma concentration of aldosterone 
decreased initially from 74 to 21pg/ml after 1 month 
of captopril administration.  Thereafter the plasma 
concentration of aldosterone began to rise,  reaching a 
level of 165pg/ml after one year.  During long-term 
captopril therapy the plasma renin activity remained 
elevated and the plasma Ang II concentration sup-
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pressed.  A sizeable and lasting hypotensive eﬀect was 
observed in all patients.  Afterwards the aldosterone 
breakthrough phenomenon came to be widely known.
　 Based on a review of the literature [5],  the inci-
dence of the aldosterone breakthrough phenomenon 
ranges from 10ｵ over 6 months to 53ｵ over 1 year.  
This phenomenon could have important clinical conse-
quences because increased aldosterone in a high-salt 
state may facilitate cardiovascular and renal damage 
in hypertensive patients [6,  7].  Two major studies,  
RALES (Randomized Aldactone Evaluation Study) 
[8] and EPHESUS (Eplerenone Post-Acute Myocar-
dial Infarction Heart Failure Eﬃcacy and Survival 
Study) [9],  indicated that aldosterone blockage pre-
vents cardiovascular and renal damage.  There is 
increasing evidence suggesting that aldosterone exerts 
physiologically and/or pathophysiologically critical 
eﬀects on the cardiovascular system [10],  kidney 
[11,  12],  and central nervous system [13] in addi-
tion to its well-established role in regulating body 
electrolyte and water homeostasis.
　 Involvement of various in vivo factors such as 
adrenocorticotropin (ACTH),  electrolytes,  endothe-
lins and Ang II type 2 receptor (AT2R) actions [14] 
have been proposed to explain the aldosterone break-
through phenomenon; however,  the detailed underly-
ing mechanism remains unknown.  We previously 
reported the presence of a functional bone morphoge-
netic protein (BMP) and activin system complete with 
ligands including BMP-6,  activins,  and their recep-
tors in human adrenocortical H295R cells [15].  We 
also reported that BMP-6 enhances Ang II- but not 
potassium (K)-induced aldosterone production through 
activating the extracellular signal-regulated kinase 
(ERK) 1/2 pathway [16].
　 Furthermore,  we investigated whether aldosterone 
breakthrough occurs in vitro using human adrenocorti-
cal cells [17].  Ang II stimulated aldosterone produc-
tion in adrenocortical cells,  which was dose-depend-
ently blocked by the ARB candesartan.  Interestingly,  
candesartanʼs eﬀects in reducing Ang II-induced aldos-
terone synthesis and CYP11B2 expression were 
impaired in the course of candesartan treatment for 15 
days.  Levels of AT1R mRNA were not changed by 
chronic candesartan treatment,  suggesting that down-
regulation of AT1R was not critical in this phenome-
non.  We here discuss BMP-6 actions in aldosterone 
regulation,  which is presumably involved in the aldos-
terone breakthrough occurring with long-term ARB 
treatment in human adrenocortical cells.
Biosynthesis of Aldosterone  
in the Adrenal Cortex
　 Aldosterone is synthesized from cholesterol in the 
zona glomerulosa of the adrenal cortex [18,  19] 
(Fig.  1).  First,  cholesterol is transferred into the 
mitochondria by the steroidogenic acute regulatory 
protein (StAR).  StAR is present in all steroidogenic 
tissues and is considered to be the rate-limiting 
enzyme.  Following translocation to the mitochondria,  
cholesterol is converted to aldosterone by a series of 
enzymatic reactions,  many of which belong to the 
cytochrome P450 (CYP) superfamily.  Cholesterol is 
converted to pregnenolone by the P450 side-chain 
cleavage enzyme (P450scc),  encoded by the CYP11A1 
gene.  Pregnenolone is released into the cytosol and is 
converted to progesterone by 3β-hydroxysteroid 
dehydrogenase (3β-HSD).  There are two 3β-HSD 
isoenzymes encoded by the HSD3B1 and HSD3B2 
genes.  Although HSD3B1 can carry out the same 
function as HSD3B2,  these enzymes localize in diﬀer-
ent tissues including adrenal and gonadal tissues for 
type 2 and placental and nonsteroidogenic tissues for 
type 1 enzyme.
　 Progesterone is converted to 11β-deoxycorticos-
terone (DOC) by 21-hydroxylase encoded by the 
CYP21A gene.  P450 aldosterone synthase 
(P450aldo) located in the mitochondria of the zona 
glomerulosa and encoded by the CYP11B2 gene,  
which converts DOC to corticosterone with 11β
-hydroxylation,  corticosterone to 18-hydroxycorticos-
terone with 18-hydroxylation,  and ﬁnally 18-hydroxy-
corticosterone to aldosterone with 18-oxidation.  
Recent studies have suggested the existence of extra-
adrenal aldosterone production in the heart and blood 
vessels [20].  Nevertheless,  there is still an argument 
against the pathophysiological signiﬁcance of local 
aldosterone because of its very low production.
Regulation of Adrenocortical Aldosterone 
Production
　 Various factors including adrenaline,  dopamine,  
vasoactive intestinal polypeptide,  serotonin,  ouabain,  
atrial natriuretic peptide,  heparin and adrenomedullin 
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have been shown to be regulators of aldosterone pro-
duction [21,  22].  However,  production of aldoster-
one is regulated primarily by Ang II and K and,  to a 
lesser degree,  by ACTH.
　 Ang II action is transduced through the 1,  2-dia-
cylglycerol (DAG)/protein kinase C (PKC) and the 
inositol 1,  4,  5-trisphosphate (IP3)/Ca2＋ signaling 
mechanism via AT1R [23].  IP3 increases intracellu-
lar Ca2＋ inﬂux,  causing several Ca2＋/calmodulin-
dependent protein kinases (CaM kinases) to phospho-
rylate and activate transcription factors such as 
activating transcription factor (ATF)-1,  cAMP-
response-element (CRE)-binding protein (CREB),  and 
NURR-1/NGFIB.  These bind CRE and other cis-
acting elements such as Ad-5 and NBRE-1,  which are 
unique to the 5ʼ-untranslated region of the CYP11B2 
gene.  The NBRE-1 and Ad-5 cis-elements are speciﬁc 
to CYP11B2.  Additionally,  mitogen-activated protein 
kinase (MAPK) pathways have also been implicated in 
Ang II-induced aldosterone production [24,  25].
　 Increased extracellular K causes cell membrane 
depolarization.  K-induced depolarization activates 
voltage-dependent Ca2＋ channels and increases Ca2＋ 
inﬂux.  This activates calmodulin and CaM kinases,  
and ﬁnally stimulates CYP11B2 gene transcription 
[26].  ACTH acts primarily through cAMP/protein 
kinase A (PKA),  but it also stimulates Ca2＋ inﬂux.  In 
the early phase,  ACTH stimulates aldosterone syn-
thesis.  In contrast,  chronic exposure to ACTH sup-
presses aldosterone production.  The mechanism of 
aldosterone reduction by chronic ACTH treatment is 
unclear but cAMP may downregulate the expression 
of Ang II receptors.  Alternatively,  ACTH may divert 
precursors from the mineralocorticoid to the glucocor-
ticoid pathway [26].
































Fig. 1　 Aldosterone biosynthesis in the adrenal cortex.  Cholesterol is converted to pregnenolone by the P450 side-chain cleavage 
enzyme (P450scc),  to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD),  and to 11β-deoxycorticosterone (DOC) by 
21-hydroxylase.  P450 aldosterone synthase (P450aldo),  which is located in the zona glomerulosa,  converts DOC to corticosterone,  corti-
costerone to 18-hydroxycorticosterone,  and ﬁnally 18-hydroxycorticosterone to aldosterone.
BMP Actions in Regulating Aldosterone 
Production
　 Bone morphogenetic proteins (BMPs) were identi-
ﬁed in 1965 by Urist as the active components in 
demineralized bone and bone extracts that are capable 
of inducing bone formation at ectopic sites [27].  
Shortly after the cloning of the ﬁrst BMPs,  a number 
of new BMP family genes were identiﬁed using 
homology-based cDNA cloning.  BMPs regulate cell 
growth,  apoptosis,  diﬀerentiation,  and cell patterning 
and speciﬁcation in numerous tissues [28].  Recent 
studies have shown that BMPs also exhibit multifunc-
tional activities in many endocrine tissues [29] 
including ovary [30,  31],  pituitary,  hypothalamus 
[32],  thyroid [33] and adrenal [15,  16] tissues.
　 BMP type I and type II receptors independently 
have certain aﬃnity for the ligand (Fig.  2).  BMP 
binds to the type II receptor,  and then the phosphory-
lated type I receptors activate the downstream signal-
ing molecules Smads.  Among the receptor-regulated 
Smad antibodies (R-Smads),  Smad1/5/8 is activated 
in response to BMPs,  whereas Smad2/3 is activated 
in response to TGF-β and activin.  They interact with 
a common-mediator Smad (Co-Smad: Smad4) to form 
a hetero-oligomeric complex with Smad1/5/8.  The 
complex then translocates to the nucleus,  where it 
binds to target DNA and induces the transcription of 
speciﬁc genes.  Inhibitory Smads (I-Smads: Smad6/7) 
compete with Smad4 and consequently regulate the 
transcription of its gene products.
　 We have recently reported the presence of a func-
tional BMP and activin system complete with ligands 
including BMP-6 and activin βA/βB; receptors 
including activin receptor-like kinase (ALK)-2,  -3,  
and -4,  activin type II receptor (ActRII),  and BMP 
type II receptor (BMPRII); and the binding protein 
follistatin in human adrenocortical H295R cells [15].  
Activin and BMP-6 cause concentration-dependent 
increases in aldosterone production with increased 
expression of StAR,  P450scc and CYP11B2.  BMP-6 
enhances Ang II-induced but not ACTH-induced aldos-
terone production,  whereas activin enhances ACTH-
induced aldosterone production.  Activin regulates 
aldosterone synthesis predominantly by modulating the 
ACTH-cAMP-PKA signaling pathway [15].  
However,  BMP-6 contributes to Ang II-induced aldos-
terone production by activating Smad1/5/8 after 
binding to ALK-2 and/or ALK-3 in combination with 
ActRII; this aldeosterone production in turn sustains 
Ang II-induced extracellular signal-regulated kinase 
(ERK) activation [16].














































Fig. 2　 BMP system and the signaling pathway.  Each BMP ligand has preferential combinations of type I and type II BMP receptors.  
After ligand binding to the BMP receptors,  phosphorylated type I receptors subsequently phosphorylate receptor-activated Smads 
(R-Smads),  which associate with common-mediator Smad (Co-Smad) and enter the nucleus,  where they regulate gene expression.  
Inhibitory Smads (I-Smads) prevent the association between R-Smads and Co-Smads.
Involvement of BMP-6 in Aldosterone 
Breakthrough Phenomenon
　 Ang II-induced aldosterone production in human 
adrenocortical cells is concentration-dependently 
blocked by ARB [17].  However,  the ARB eﬀects on 
reducing Ang II-induced aldosterone production and 
CYP11B2 expression are impaired in the course of 
ARB treatment for 15 days.  We presumed that this 
phenomenon is a possible cellular aldosterone break-
through (Fig.  3).  Chronic ARB treatment has no 
eﬀects on AT1R expression,  suggesting that down-
regulation of AT1R is not critical in this phenomenon.  
Ang II-induced ERK1/2 signaling is blocked by ARB 
treatment; however,  the BMP-6 eﬀects on Ang 
II-induced ERK1/2 become resistant to ARB in the 
chronic phase.  BMP-6-induced Smad1/5/8 activation 
is in turn ampliﬁed in cells chronically treated with 
Ang II plus ARB compared with cells treated with Ang 
II alone.  Cellular expression of BMP-6 and its recep-
tor including ALK-2 and ActRII are decreased by 
chronic Ang II exposure but restored by co-treatment 
with ARB (Fig.  3).  Collectively,  changes in BMP-6 
availability and response may be involved in the occur-
rence of cellular escape from aldosterone suppression 
under chronic treatment with ARB.
Conclusion
　 Various factors such as ACTH,  electrolytes,  
endothelins and Ang II type 2 receptor actions have 
been proposed as the cause of aldosterone break-
through.  We here found that long-term ARB treat-
ment reverses the reduction of aldosterone synthesis 
by adrenocortical cells,  leading to “cellular aldoster-
one breakthrough”.  Since in vitro breakthrough was 
attenuated by the neutralization of endogenous BMP-6 
and ALK-2,  BMP-6 availability in the adrenal cortex 
may be involved in the occurrence of cellular escape 
from aldosterone suppression under chronic treatment 
with ARB.
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